Cellular Goods PLC (LSE:CBX) said its cannabidiol (CBD) and cannabigerol (CBG) blends are capable of counteracting skin ageing effects equally and, in some cases, more effectively than vitamin c treatments that dominate the multi-billion-dollar market.
Its cannabinoid formulations were also found suitable for sensitive skin, a recently published white paper from the company also confirmed.
Chief executive Anna Chokina said: "Cellular Goods is on a mission to become the most innovative listed wellness company and the release of today's white paper shows our commitment to the ground-breaking science that will drive the industry forward.
“CBD and CBG have very promising skincare applications and we are delighted to be able to share our findings.
“Delivering efficacy-led and research-backed products is at the heart of the Cellular brand ethos and this approach will ensure that our products take full advantage of all the benefits that lab-made cannabinoids can offer.”
External factors such as inflammation and exposure to ultra-violet light can cause wrinkles and fine lines, and make the skin lose its elasticity and volume.
Within the cosmetics industry, a wide range of skincare products rely on active ingredients such as vitamin C, retinoids, and exfoliating acids to help address these effects.
The latest research suggests the skin-care market could grow to almost US$48bn by 2027, so having a new ‘promising’ product that is shown to be superior to current treatments on the market could have significant commercial ramifications.
"We are proud to be the first to bring products formulated with CBG to the UK,” said Cellular CEO Chokina.
“CBG is the most promising cannabinoid for skincare applications and pioneering its use sets Cellular apart from the competition."
The UK-based wellness company provides premium products formulated with lab-made cannabinoids.